Chesley Taft & Associates LLC lessened its holdings in shares of Celgene Co. (NASDAQ:CELG) by 95.1% during the fourth quarter, HoldingsChannel reports. The firm owned 8,905 shares of the biopharmaceutical company’s stock after selling 172,635 shares during the quarter. Chesley Taft & Associates LLC’s holdings in Celgene were worth $929,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Arcadia Investment Management Corp MI lifted its holdings in shares of Celgene by 118.7% during the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 400 shares during the period. Thompson Davis & CO. Inc. lifted its holdings in shares of Celgene by 5.9% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after acquiring an additional 43 shares during the period. Robecosam AG bought a new stake in shares of Celgene during the 3rd quarter worth approximately $114,000. Capital Bank & Trust Co lifted its holdings in shares of Celgene by 166.8% during the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 517 shares during the period. Finally, Guidant Wealth Advisors bought a new stake in shares of Celgene during the 3rd quarter worth approximately $119,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.

Celgene Co. (NASDAQ CELG) opened at $92.51 on Friday. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 3.52. Celgene Co. has a 12-month low of $88.32 and a 12-month high of $147.17. The stock has a market cap of $70,720.00, a P/E ratio of 25.63, a price-to-earnings-growth ratio of 0.65 and a beta of 1.49.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The firm had revenue of $3.48 billion during the quarter, compared to analysts’ expectations of $3.46 billion. During the same period in the prior year, the company posted $1.61 EPS. The company’s revenue was up 16.9% on a year-over-year basis. equities research analysts predict that Celgene Co. will post 7.68 earnings per share for the current year.

In other Celgene news, insider Mark J. Alles purchased 3,260 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was purchased at an average cost of $91.90 per share, for a total transaction of $299,594.00. Following the transaction, the insider now owns 178,904 shares in the company, valued at approximately $16,441,277.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.95% of the company’s stock.

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald set a $112.00 price target on shares of Celgene and gave the stock a “hold” rating in a report on Tuesday, January 23rd. UBS Group downgraded shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 price target for the company. in a report on Thursday, October 26th. BMO Capital Markets cut their price target on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Robert W. Baird downgraded shares of Celgene from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $162.00 to $136.00 in a report on Friday, October 20th. Finally, BTIG Research reaffirmed a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $130.35.

TRADEMARK VIOLATION NOTICE: “Chesley Taft & Associates LLC Has $929,000 Holdings in Celgene Co. (CELG)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2018/02/11/chesley-taft-associates-llc-has-929000-holdings-in-celgene-co-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.